Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Completion of conversion of A shares to B shares in 2-03-2023, 15:18

BUSINESSNEXT & DATANEXT achieve Red Hat Certification for Containerized Applications 6-06-2023, 15:48